Repositório Covid-19

SUMMARYSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused aworldwide outbreak, known as coronavirus disease 2019 (COVID-19). Alongsidevaccines, antiviral therapeutics...

Introduction

There is a need to protect vulnerable individuals who do not respond to vaccination against severe acute respiratory syndrome...

Abstract

Studying viral–host protein–protein interactions can facilitate the discovery of therapies for viral infection. We use high-throughput yeast two-hybrid experiments...

Summary

Background

KL-A167 is a fully humanized monoclonal antibody targeting programmed cell death-ligand 1. This phase 2 study aimed to...

Summary

Background

Intranasal vaccination may induce protective local and systemic immune responses against respiratory pathogens. A number of intranasal SARS-CoV-2...

The idiopathic Coronavirus disease 2019 (COVID-19) pandemic outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has reached...

Abstract

In late 2019 the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus emerged in China and quickly spread into...

While new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constantly emerge to prolong the pandemic of COVID-19, robust...

Abstract

The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a...

BACKGROUND

The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster vaccine are not known.

Background

Updated immunization strategies are needed to address multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Here we report interim...